FDA staff told the panelists they recommended against giving compounders the green light due to a lack of clinical evidence demonstrating safety and efficacy.
No event time was recorded for this claim — the text gave nothing to anchor it to, and a guessed date would be worse than none.
Standing
lens: Evidence-weighted Structural
No belief has been computed for this claim under Evidence-weighted yet.
What bears on it
Nothing supports or challenges this claim yet — untested, which is not the same as refuted.
Voices
- STAT independent
Voices are counted, never weighed. How many people say a thing is structure worth seeing; it is not, by itself, a reason to believe it.
What the documents actually said
The verbatim text each extraction read before resolving it into this canonical claim. Quoted, never republished.
- FDA staff told the panelists they recommended against giving compounders the green light due to a lack of clinical evidence demonstrating safety and efficacy.
For each peptide under consideration, FDA staff told the panelists they recommended against giving compounders the green light due to a lack of clinical evidence demonstrating safety and efficacy.
Sources
Origin: extracted from FDA advisory panel narrowly rejects compounding of one peptide, backs two others · 2026-09-11 07:34